LONDON, July 29, 2024 - Plug and Play UK Health has announced the second cohort of startups for its 12-week Health Accelerator Program. This new batch marks a significant step in advancing healthcare innovation in the UK while maintaining a global perspective.
Eleven startups have been selected for this program, which contributes to the West Midlands Health Tech Innovation Accelerator (WMHTIA) and supports regional innovation and research and development (R&D).
The cohort represents a broad spectrum of healthcare sectors, stages of development, and geographical locations, with a particular emphasis on the West Midlands. These startups showcase the program's commitment to fostering international growth and commercial success. The batch features innovative healthcare solutions, including rapid bacterial identification systems, oximetry and post-surgery monitoring tools, advanced transdermal drug delivery and pharmaceutical carrier technologies, and AI-powered tools aimed at enhancing diagnosis, prescribing, and record-keeping.
The Advisory Board for this cohort has been expanded to include a distinguished group of corporate and key partners. The board features leading pharmaceutical companies such as Roche, Johnson & Johnson, Haleon, and Daiichi Sankyo, as well as major health insurance providers including BUPA and Aviva. Additionally, the board includes strategic partners such as BT, NHS, The Alan Turing Institute, and other investors.
The cohort will be mentored by an assembly of mentors from Plug and Play global offices, government, universities, and accomplished entrepreneurs and investors, further enhancing the program's impact.
As a leading innovation platform, Plug and Play continues to play a key role in the global commercialization of healthcare innovations.
“We are proud to bring Plug and Play Health to the UK and be selected as one of the delivery organizations of the WMHTIA. Plug and Play have been investing, accelerating, and supporting startups to scale for over 30 years; we are excited to support a new generation of world-changing companies through our global healthcare ecosystem,” said Kieran Borrett, Director of Plug and Play UK.
The Health Accelerator Program, designed to support companies on their commercial journey, leverages Plug and Play's extensive network to facilitate the securing of first commercial pilots or customers.
The 11 startups that have been selected to participate in the program are:
Ademen (https://www.ademen.io/) offers discreet, longitudinal capture and analysis of bowel activity for improved diagnosis and personalized treatment.
Cytecom (https://www.cytecom.co.uk/) is developing a groundbreaking approach to diagnosing bacterial infections.
Earswitch (https://www.earswitch.co.uk/) provides a unique end-to-end, in-ear biometric sensor and control technology, enabling racially inclusive oximetry.
Genomate (https://www.genomate.health/) is developing AI-powered computational tools for personalized medicine.
Holly Health (https://hollyhealth.io/) offers a suite of digital health coaching services, with intelligence, aimed at personalized lifestyle behavior change and chronic condition coaching.
Intelligent Assist (https://iamyhealth.com/) is developing an AI-enabled Electronic Health Record system that captures patient data continuously, providing intelligently analyzed data.
Medherant (https://www.medherant.co.uk/) is developing innovative treatments using its novel transdermal drug delivery technology.
Medicaite (https://www.medicaite.com/) is developing a precision healthcare engine that assists prescribing based on patient characteristics, guideline recommendations and AI.
Mesox (https://mesox.co.uk/) is transforming the way pharmaceuticals are formulated through carrier technologies providing enhanced bioavailability at speed.
Praxium AI (https://praxium.ai/) is developing an AI-powered software to significantly speed up radiology diagnosis times.
Pyrexia (https://www.pyrexia.io/) offers an intelligent suite of tools for healthcare administrators, managers, workforce and HR teams.
These innovative companies will undergo a tailored 12-week support program with Plug and Play and its extensive partner network, culminating in a grand Expo in Birmingham, United Kingdom in October 2024.
Funded by the Department for Science, Innovation & Technology and delivered in partnership with Innovate UK and the West Midlands Combined Authority, the WMHTIA is set to shape the future of healthcare innovation in the West Midlands.
For inquiries regarding partnership opportunities or participation in future batches, please contact Health Program Manager Adam McGuinness at a.mcguinness@pnptc.com, or Ventures Associate Polina Stavrovski at p.stavrovski@pnptc.com.
About Plug and Play
Plug and Play is the leading innovation platform, connecting startups, corporations, venture capital firms, universities, and government agencies. Headquartered in Silicon Valley, we're present in 60+ locations across 5 continents. We offer corporate innovation programs and help our corporate partners in every stage of their innovation journey, from education to execution. We also organize startup acceleration programs and have built an in-house VC to drive innovation across multiple industries where we've invested in hundreds of successful companies including Dropbox, Guardant Health, Honey, Lending Club, N26, PayPal, and Rappi. For more information, visit www.plugandplaytechcenter.com/.
About West Midlands Health Tech Innovation Accelerator
The West Midlands Health Tech Innovation Accelerator (WMHTIA) is focused on helping companies drive their innovations towards market success. Uniting 20 partners across academia, industry and NHS under one cohesive programme – the WMHTIA provides companies access to essential services and expertise that are pivotal in critically developing technologies. The £16m WMHTIA is funded by the Department for Science, Innovation & Technology, in partnership with Innovate UK and the West Midlands Combined Authority.
Media Contact: